Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now official registry

Unspecified Adult Solid Tumor, Protocol Specific clinical trials

5 of 112 indexed Unspecified Adult Solid Tumor, Protocol Specific trials are currently recruiting.

112 US clinical trials · 5 currently recruiting

Unspecified Adult Solid Tumor, Protocol Specific is the subject of 112 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 10 are in Phase 3-4 (later-stage) and 93 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 26 of these trials.

The research picture

Unspecified Adult Solid Tumor, Protocol Specific has 112 registered US clinical trials, 5 of them open to new participants right now, about 4% of the total.

5
recruiting participants now
4%
of trials open to enrollment
10
in Phase 3–4 (later-stage)
26
top sponsor: National Cancer Institute (NCI)
Phase 185Phase 28Phase 310

Active & Recent Trials

112 total, page 2 of 3

COMPLETED Phase 1 38 participants

Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy

Mayo Clinic

NCT00949949

COMPLETED Phase 2 35 participants

Stereotactic Body Radiation Therapy and Vertebroplasty in Treating Patients With Localized Spinal Metastasis

University of Texas Southwestern Medical Center

NCT00855803

COMPLETED Phase 1 33 participants

Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors

Case Comprehensive Cancer Center

NCT00253344

COMPLETED Phase 1 30 participants

Sirolimus in Treating Patients With Metastatic or Unresectable Solid Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT00368914

COMPLETED Phase 1 30 participants

Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors

Memorial Sloan Kettering Cancer Center

NCT00423865

COMPLETED Phase 1 30 participants

Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors

University of California, Davis

NCT00389584

COMPLETED Phase 1 29 participants

Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors

University of Nebraska

NCT01206465

COMPLETED Phase 1 29 participants

Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients

Pfizer

NCT01337765

COMPLETED Phase 1 28 participants

O(6)-Benzylguanine and Carmustine in Treating Patients With Solid Tumors

Case Comprehensive Cancer Center

NCT00002604

COMPLETED Phase 1 28 participants

BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

NCT00022529

COMPLETED Phase 2 27 participants

Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy

Northwestern University

NCT01898130

COMPLETED Phase 1 27 participants

1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors

National Cancer Institute (NCI)

NCT01191216

COMPLETED Phase 1 27 participants

Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity

City of Hope Medical Center

NCT00825201

COMPLETED Phase 1 26 participants

Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer

Edward Kim

NCT01924260

COMPLETED Phase 1 26 participants

Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers

Roswell Park Cancer Institute

NCT01497392

COMPLETED Phase 1 25 participants

Combination Chemotherapy With or Without Filgrastim in Treating Patients With Advanced Solid Tumors

University of Pittsburgh

NCT00008125

COMPLETED Phase 1 25 participants

Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment

City of Hope Medical Center

NCT00544284

COMPLETED Phase 1 25 participants

Perillyl Alcohol in Treating Patients With Refractory Cancer

National Cancer Institute (NCI)

NCT00002862

COMPLETED Phase 1 25 participants

Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer

Yale University

NCT00002950

COMPLETED Phase 1 24 participants

Decitabine in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

NCT00030615

COMPLETED Phase 1 24 participants

Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer

Roswell Park Cancer Institute

NCT00003294

COMPLETED Phase 1 24 participants

Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors

National Cancer Institute (NCI)

NCT00079352

COMPLETED Phase 2 24 participants

Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors

Georgetown University

NCT00003125

COMPLETED Phase 1 24 participants

3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Recurrent Tumors

Fox Chase Cancer Center

NCT01470365

COMPLETED Phase 1 24 participants

Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors

National Cancer Institute (NCI)

NCT00112476

COMPLETED Phase 1 23 participants

ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer

National Institutes of Health Clinical Center (CC)

NCT00387608

COMPLETED Phase 1 22 participants

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Case Comprehensive Cancer Center

NCT00006465

COMPLETED Phase 1 21 participants

Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

California Cancer Consortium

NCT00387504

COMPLETED Phase 1 21 participants

Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer

University of Chicago

NCT00002939

COMPLETED Phase 1 19 participants

An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function

Eisai

NCT01418677

COMPLETED Phase 1 15 participants

Calcitriol, Ketoconazole, and Dexamethasone in Treating Patients With Metastatic or Unresectable Solid Tumors

Roswell Park Cancer Institute

NCT00238225

COMPLETED Phase 1 13 participants

Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid Tumors

University of Southern California

NCT01957995

COMPLETED Phase 1 12 participants

SU6668 in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

NCT00024206

COMPLETED Phase 1 9 participants

BMS-599626 in Treating Patients With Metastatic Solid Tumors

Jonsson Comprehensive Cancer Center

NCT00093730

COMPLETED Phase 1 3 participants

Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma

National Cancer Institute (NCI)

NCT00002759

COMPLETED Phase 1

PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma

NYU Langone Health

NCT00004002

COMPLETED Phase 1

Indole-3-Carbinol in Preventing Cancer in Healthy Participants

University of Kansas

NCT00100958

COMPLETED NA

Patient Education in Preventing Nausea and Vomiting in Cancer Patients Receiving Chemotherapy

University of Rochester

NCT00005994

COMPLETED Phase 2

Vaccine Therapy in Treating Patients With Metastatic Cancer

National Cancer Institute (NCI)

NCT00021164

COMPLETED Phase 1

BMS-247550 and Gemcitabine in Treating Patients With Advanced Solid Tumors

Memorial Sloan Kettering Cancer Center

NCT00043095

COMPLETED Phase 1

3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer

Vion Pharmaceuticals

NCT00016874

COMPLETED Phase 1

BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy

National Cancer Institute (NCI)

NCT00020371

COMPLETED Phase 1

Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer

National Cancer Institute (NCI)

NCT00019656

COMPLETED Phase 1

UCN-01 in Treating Patients With Advanced Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT00003289

COMPLETED Phase 1

SU5416, Irinotecan, and Cisplatin in Treating Patients With Advanced Solid Tumors

Ohio State University Comprehensive Cancer Center

NCT00006000

COMPLETED Phase 1

Perifosine in Treating Patients With Advanced Solid Tumors

University of Wisconsin, Madison

NCT00005794

COMPLETED Phase 1

Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors

Dartmouth-Hitchcock Medical Center

NCT00014261

COMPLETED Phase 1

Vaccine Therapy in Treating Patients With Advanced Cancer

Jonsson Comprehensive Cancer Center

NCT00004881

COMPLETED Phase 1

PS-341 in Treating Patients With Advanced Cancer

Mayo Clinic

NCT00006362

COMPLETED Phase 1

Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors

Memorial Sloan Kettering Cancer Center

NCT00004059

← Previous Page 2 of 3 Next →

Phase Distribution

PhaseTrial count
Phase 1 85
Phase 2 8
Phase 3 10

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the Unspecified Adult Solid Tumor, Protocol Specific Trial Landscape

112 indexed Unspecified Adult Solid Tumor, Protocol Specific studies · 5 recruiting (4%).

Phase mix: 10 late (III/IV) vs 93 early (I/II).

Top sponsor: National Cancer Institute (NCI) (26 trials), 9 others listed. 50 shown below, recruiting first.

How to read this condition's trial landscape

That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation, eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for Unspecified Adult Solid Tumor, Protocol Specific?

PlainTrial tracks 112 US clinical trials for Unspecified Adult Solid Tumor, Protocol Specific, of which 5 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Unspecified Adult Solid Tumor, Protocol Specific?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.